Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,148
datasets available to search
ShareScore release 0.9.0
Dataset results
2,148 results for “HER2”
Detection of HER2+ Breast Cancer Cells using Bioinspired DNA-Based Signal Amplification
<p>Circulating tumor cells (CTC) are promising biomarkers for metastatic cancer detection and monitoring progression. However, CTC detection remains challenging due to their low frequency and heterogeneity. Herein, we report a bioinspired approach to detect individual cancer cells, based on a signal amplification cascade using a programmable DNA hybridization chain reaction (HCR) circuits. We applied this approach to detect HER2+ cancer cells using the anti-HER2 antibody (trastuzumab) coupled to initiator DNA eliciting a HCR cascade that leads to a fluorescent signal at the cell surface. At 4°C, this HCR detection scheme resulted in highly efficient, specific and sensitive signal amplification of the DNA hairpins specifically on the membrane of the HER2+ cells in a background of HER2- cells and peripheral blood leukocytes, which remained almost non-fluorescent. The results indicate that this system offers a new strategy that may be further developed toward an in vitro diagnostic platform for the sensitive and efficient detection of CTC.</p>
2 million histological images of breast cancer tumors with her2 labels
<p><strong>Data Description</strong><br> This is a 2 million set of non-overlapping image patches from hematoxylin & eosin (H&E) stained histological images of human breast cancer tumor tissue.</p> <p>The anonymized dataset comes from a cohort of BC patients from the A. C. Camargo Cancer Center (ACCCC, N = 504). All patients were treated for breast cancer at the ACCCC between 2019 and 2021. As part of their diagnosis, in HER2 IHC score 2+ cases, patients' HER2 status was determined following the ASCO guidelines updated in 2018, with visual evaluation of IHC assay and either a FISH or DDISH test. All cases with metastasis or neoadjuvant treatment were excluded.</p> <p>A total of 426 H&E stained high resolution images (40x magnification) were scanned from biopsy and resection tissue samples with a Leica Aperio AT2 scanner. Ethical approval of the ACCCC study was given by the ethics committee of the Fundação Antônio Prudente. We divided the cases into the following 3 groups according to the results of the IHC and ISH tests: HER2-negative, HER2-low and HER2-high.</p> <p>The slides were divided into 256 px x 256 px tiles at 0.5 um/pixel magnification. Then, we used a custom trained ConvNext-tiny neural network to only include tiles from the tumor region and its environment, generating a total of 2051877 image patches.</p> <p>A sample is considered her2-negative with an IHC score of 0; her2-low with an IHC score of 1+ or an IHC score of 2+ with a negative ISH-based test result, and her2-high with an IHC score of 2+ with a positive ISH-based test or an IHC score of 3+.</p> <p>The accompanying code used for training the models is available at https://github.com/tojallab/wsi-mil</p>
HER2 overexpression in gastroesophageal adenocarcinoma from immunohistochemstry imaging.
<p><strong>HER2 overexpression in gastroesophageal adenocarcinoma from immunohistochemstry imaging.</strong></p> <p>Primary dataset used in <em>Predicting the HER2 status in esophageal cancer from tissue microarrays using convolutional neural networks </em>[1]<em>.</em></p> <p>This dataset is composed by HER2 immunohistochemistry images of gastroesophageal adenocarcinoma patients. We provide a train-test split of .jpg image files of individual tissue cores, which were labeled with an immunohistochemstry score (ranging from 0 to 3) and a HER2 overexpression status (positive or negative).</p> <p> </p> <p><em>Detailed information</em></p> <p>Train split comes from a multi-spot tissue microarray (TMA) with 165 tumor cases and a single-spot TMA with 428 tumor cases, as described elsewhere [2]. Test split comes from an independent single-spot TMA with 307 tumor cases as the test dataset. The test set consisted of tumor cases that occurred at a later time point compared to the training set cases. This dataset construction strategy mimics how such a model would be developed and deployed in a clinical routine. Coincidentally, the test set does not include tumor cases with an IHC score of 1. The multi-spot TMA was composed of eight tissue cores (1.2 mm diameter) of each tumor - four cores punched on the tumor margin and four in the tumor center. To construct the single-spot TMA, one tissue core per patient from the tumor center was punched. The cores were transferred to TMA receiver blocks. Each TMA block contained 72 tissue cores. Subsequently, 4 µm-thick sections from the TMA blocks were prepared and transferred to an adhesive-coated slide system (Instrumedics Inc., Hackensack, NJ).</p> <p>We used a HER2 antibody (Ventana clone 4B5, Roche Diagnostics, Rotkreuz, Switzerland) on the automated Ventana/Roche slide stainer to perform immunohistochemistry (IHC) on the TMA slides. HER2 expression in carcinoma cells was assessed according to staining criteria listed in the Supplemental Table 1 of [1]. Scores 0 and 1 indicated negative HER2 status, and score 3 indicated positive HER2 status. Immunohistochemical expression evaluation was assessed manually by two pathologists according to [3]. Discrepant results, which occurred only in a small number of samples, were resolved by consensus review. Spots with a score of 2 were analyzed by fluorescence in situ hybridization (ISH) to resolve the HER2 status. The ISH analysis evaluated the HER2 gene amplification status using the Zytolight SPEC ERBB2/CEN 17 Dual Probe Kit (Zytomed Systems GmbH, Germany) according to the manufacturer's protocol. A fluorescence microscope (DM5500, Leica, Wetzlar, Germany) with a 63× objective was used for scanning the tumor tissue for amplification hotspots. We counted the signals in randomly chosen areas of homogeneously distributed signals. Twenty tumor cells were evaluated by counting green HER2 and orange centromere-17 (CEN17) signals. The reading strategy followed the recommendations of HER2/CEN17 ratio ≥ 2.0 or HER2 signals ≥ 6.0 for HER2 positive and a HER2/CEN17 ratio < 2.0 for HER2 negative samples.</p> <p>Slides were digitised with a slide scanner (NanoZoomer S360, Hamamatsu Photonics, Japan) with 40-times magnification and used QuPath's [4] TMA dearrayer to slice the digitized slides into individual images.</p> <p> </p> <p>[1] Pisula JI, Datta RR, Boerner-Valdez L, Avemarg JR, Jung JO, Plum P, Loeser H, Lohneis P, Meuschke M, dos Santos DP, Gebauer F, et al. Predicting the HER2 status in esophageal cancer from tissue microarrays using convolutional neural networks. bioRxiv: https://www.biorxiv.org/content/10.1101/2022.05.13.491769v1</p> <p>[2] Plum PS, Gebauer F, Krämer M, Alakus H, Berlth F, Chon SH, Schiffmann L, Zander T, Büttner R, Hölscher AH, Bruns CJ. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma. BMC cancer. 2019 Dec;19(1):1-9.</p> <p>[3] Lordick F, Al-Batran SE, Dietel M, Gaiser T, Hofheinz RD, Kirchner T, Kreipe HH, Lorenzen S, Möhler M, Quaas A, Röcken C. HER2 testing in gastric cancer: results of a German expert meeting. Journal of cancer research and clinical oncology. 2017 May;143(5):835-41.</p> <p>[4] Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG, James JA. QuPath: Open source software for digital pathology image analysis. Scientific reports. 2017 Dec 4;7(1):1-7.</p>
Immune and genetic signature of HER2-driven breast carcinomas triggering anti-Yo paraneoplastic cerebellar degeneration
<ul> <li>Supplementary eTables from: Immune and genetic signature of HER2-driven breast carcinomas triggering anti-Yo paraneoplastic cerebellar degeneration: <ul> <li><strong>eTables 1</strong>: Results of DESeq2 on the differential gene expression analysis between Yo-PCD and control tumours for all genes and for differentially expressed genes.</li> <li><strong>eTables 2</strong>: Results of the Gene Ontology enrichment performed by clusterProfiler on genes over-expressed in Yo-PCD tumours</li> <li><strong>eTables 3</strong>: Results of the Gene Ontology enrichment performed by clusterProfiler on genes under-expressed in Yo-PCD tumours</li> </ul> </li> <li>Gene counts</li> <li>Gene TPMs</li> </ul>
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
ClinicalTrials.gov study NCT03734029. IPD Sharing: YES. Countries: 20. Publications: 8.
Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer
ClinicalTrials.gov study NCT03366428. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
ClinicalTrials.gov study NCT01160211. IPD Sharing: YES. Countries: 29. Publications: 2.
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic S
ClinicalTrials.gov study NCT01808573. IPD Sharing: YES. Countries: 28. Publications: 2.
Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer
ClinicalTrials.gov study NCT04191382. IPD Sharing: YES. Countries: 9. Publications: 1.
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
ClinicalTrials.gov study NCT03529110. IPD Sharing: YES. Countries: 15. Publications: 9.
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Can
ClinicalTrials.gov study NCT02163694. IPD Sharing: YES. Countries: 37. Publications: 5.
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
ClinicalTrials.gov study NCT04478266. IPD Sharing: YES. Countries: 30. Publications: 2.
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov study NCT04644237. IPD Sharing: YES. Countries: 10. Publications: 2.
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer
ClinicalTrials.gov study NCT01698918. IPD Sharing: YES. Countries: 13. Publications: 1.
Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer
ClinicalTrials.gov study NCT03822468. IPD Sharing: YES. Countries: 23. Publications: 1.
Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC
ClinicalTrials.gov study NCT00709761. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer
ClinicalTrials.gov study NCT01816594. IPD Sharing: YES. Countries: 4. Publications: 1.
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
ClinicalTrials.gov study NCT00820222. IPD Sharing: UNDECIDED. Countries: 14. Publications: 1.
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
ClinicalTrials.gov study NCT03523585. IPD Sharing: YES. Countries: 15. Publications: 2.
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
ClinicalTrials.gov study NCT02400476. IPD Sharing: YES. Countries: 7. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.